FOXO1 is a master regulator of memory programming in CAR T cells
10.1038/s41586-024-07300-8 · doi-reference
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
10.1038/s41586-024-07242-1 · doi-reference
Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies
10.1016/j.ccell.2020.05.004 · doi-reference
CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory
10.1158/2159-8290.cd-20-1554 · doi-reference
IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype
10.1158/2326-6066.cir-18-0466 · doi-reference
BCL6 overexpression in CD4+ T cells induces TFH-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer
10.1016/j.bbadis.2024.167346 · doi-reference
Inosine induces stemness features in CAR-T cells and enhances potency
10.1016/j.ccell.2024.01.002 · doi-reference
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
10.1038/s41598-017-00462-8 · doi-reference
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
10.1007/s00262-018-2281-2 · doi-reference
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
10.1172/jci.insight.133977 · doi-reference
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
10.1038/s41467-021-23331-5 · doi-reference
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
10.1007/s11684-017-0543-6 · doi-reference
The two faces of IL-2: a key driver of CD8+ T-cell exhaustion
10.1038/s41423-021-00712-w · doi-reference
CRTAM determines the CD4+ cytotoxic T lymphocyte lineage
10.1084/jem.20150519 · doi-reference
Regulatory T cells restrain interleukin-2-and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells
10.1016/j.immuni.2019.12.007 · doi-reference
Depletion of Tregs from CD4+ CAR-T cells enhances the tumoricidal effect of CD8+ CAR-T cells in anti-CD19 CAR-T therapy
10.1111/febs.17326 · doi-reference
Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry
10.1182/blood-2025-127 · doi-reference
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
10.1016/s0140-6736(20)31366-0 · doi-reference
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
10.1172/jci85309 · doi-reference
CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype
10.1136/jitc-2023-007803 · doi-reference
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity
10.1038/s43018-023-00570-7 · doi-reference
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy
10.1182/bloodadvances.2023012416 · doi-reference
Cytotoxic CD4+ T cells in chronic viral infections and cancer
10.3389/fimmu.2023.1271236 · doi-reference
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
10.1038/s41586-021-04390-6 · doi-reference
Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting common p53 neoantigens in human solid tumors
10.1158/2326-6066.cir-22-0040 · doi-reference
Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3
10.1200/jco.2017.74.5463 · doi-reference
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen
10.1038/icb.2016.14 · doi-reference
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes
10.1097/cji.0b013e31825898c5 · doi-reference
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
10.1084/jem.20091921 · doi-reference
Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma
10.1158/1078-0432.ccr-22-3853 · doi-reference
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
10.1136/jitc-2023-007288 · doi-reference
CD4 phenotypes are associated with reduced expansion of tumor-infiltrating lymphocytes in melanoma patients treated with adoptive cell therapy
10.4049/jimmunol.2300250 · doi-reference
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
10.1097/cco.0000000000000925 · doi-reference
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
10.1200/jco.2012.46.6441 · doi-reference
Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma
10.1172/jci98689 · doi-reference
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
10.1056/nejmoa0800251 · doi-reference
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
10.1097/00002371-200107000-00012 · doi-reference
Eradication of established tumors by CD8+ T cell adoptive immunotherapy
10.1016/s1074-7613(00)00026-1 · doi-reference
